Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Leah Byrd

Physician Assistant West Columbia, SC Physician Assistant

NPI 1336497874 CMS profile 5583342

146 N Hospital Dr Ste 550, West Columbia, SC 29169

Open in the dashboard

General payments

$2,501

105 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leah Byrd of West Columbia, SC is reported in the CMS Open Payments database as having received $2,501 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,113 47
2024 General $659 27
2023 General $627 26
2022 General $101 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leah Byrd
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Leah Byrd were reported at $1,113. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Leah Byrd Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $101 $155 $48–$522 $149
2023 $627 $167 $52–$557 $160
2024 $659 $178 $55–$600 $164
2025 $1,113 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Amgen Inc. $701 31 payments
  2. AbbVie, Inc. $674 24 payments
  3. Novartis Pharmaceuticals Corporation $218 7 payments
  4. UCB, Inc. $171 8 payments
  5. GlaxoSmithKline, LLC. $122 4 payments
  6. Genentech USA, Inc. $78 4 payments
  7. Aurinia Pharma U.S., Inc. $62 3 payments
  8. Lilly USA, LLC $54 3 payments
  9. Horizon Therapeutics plc $51 3 payments
  10. AstraZeneca Pharmaceuticals LP $49 3 payments
  11. Other $321 15 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,501 105 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $453 17 payments
  2. Enbrel $272 11 payments
  3. Otezla $225 9 payments
  4. KRYSTEXXA $218 8 payments
  5. COSENTYX $202 6 payments
  6. SKYRIZI $159 5 payments
  7. TAVNEOS $153 7 payments
  8. BENLYSTA $122 4 payments
  9. Cimzia $98 5 payments
  10. Bimzelx $73 3 payments
  11. Other $840 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,031

Median for Physician Assistant: 241

Drug cost

$1,511,111

Median for Physician Assistant: $4,110

Branded share of claims

18.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 68 $849,026
Rinvoq Upadacitinib Brand 27 $229,621
Enbrel Sureclick Etanercept Brand 14 $102,850
Xeljanz Xr Tofacitinib Citrate Brand 13 $78,580
Forteo Teriparatide Brand 13 $64,915
Otezla Apremilast Brand 11 $52,627
Kevzara Sarilumab Brand 12 $49,599
Teriparatide Generic 16 $39,965
Hydroxychloroquine Sulfate Generic 301 $10,822
Leflunomide Generic 157 $6,170

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$143,875

Of which drugs: $101,903

Medicare patients

336

Average age 72

Services billed

11,997

268 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 32%
Diabetes 29%
Depression 28%
Ischemic heart disease 27%
Chronic kidney disease 26%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 26 2,100 $42,710
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 79 724 $494
Injection, methylprednisolone acetate, 1 mg J1010 Office 18 1,280 $126

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $104
$104 27 —
KRYSTEXXA
  • Amgen Inc. $94
$94 — —
Enbrel
  • Amgen Inc. $77
$77 14 —
SKYRIZI
  • AbbVie, Inc. $61
$61 — —
Cimzia
  • UCB, Inc. $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record